scholarly journals High BANCR expression is associated with worse prognosis in human malignant carcinomas: An updated systematic review and meta-analysis

2020 ◽  
Author(s):  
Shi xu Fang ◽  
Zhou Liu ◽  
Qiang Guo ◽  
Cheng Chen ◽  
Xi xian Ke ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Smoking Status ◽  
Meta Analysis ◽  
Strong Relationship ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
China National Knowledge Infrastructure ◽  
Poor Overall Survival ◽  
Advanced Tumor

Abstract Background: BRAF-activated noncoding RNA (BANCR) is aberrantly expressed in various tumor tissues and has been confirmed to function as a tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of BANCR in various carcinomas. Methods: A comprehensive literature search of PubMed, Web of Science, EMBASE, Cochrane Library and the China National Knowledge Infrastructure (CNKI) was conducted to collect relevant articles. Results: The pooled results showed a strong relationship between high BANCR expression and poor overall survival (OS) (HR (hazard ratio) =1.60, 95% confidence interval (CI): 1.19-2.15, P =0.002) and recurrence-free survival (RFS) (HR=1.53, 95% CI: 1.27-1.85, P <0.00001). In addition, high BANCR expression predicted advanced tumor stage (OR (odds ratio) =2.39, 95% CI: 1.26-4.53, P =0.008), presence of lymph node metastasis (OR=2.03, 95% CI: 1.08-3.83, P =0.03), positive distant metastasis (OR=3.08, 95% CI: 1.92-4.96, P <0.00001) and larger tumor sizes (OR=1.63, 95% CI: 1.09-2.46, P =0.02). However, no associations were found for smoking status (OR=1.01, 95% CI: 0.65-1.56, P =0.98), age (OR=0.88, 95% CI: 0.71-1.09, P =0.236) and sex (OR=0.91, 95% CI: 0.72-1.16, P =0.469). The sensitivity analysis of OS showed that the results of each publication were almost consistent with the combined results, and the merged results have high robustness and reliability. Conclusions: The results showed that elevated BANCR expression was associated with unfavorable prognosis for most cancer patients, and BANCR could serve as a promising therapeutic target and independent prognostic predictor in most of cancer types.

scholarly journals High BANCR expression is associated with worse prognosis in human malignant carcinomas: an updated systematic review and meta-analysis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Shixu Fang ◽  
Zhou Liu ◽  
Qiang Guo ◽  
Cheng Chen ◽  
Xixian Ke ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Smoking Status ◽  
Meta Analysis ◽  
Strong Relationship ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
China National Knowledge Infrastructure ◽  
Poor Overall Survival ◽  
Advanced Tumor

Abstract Background BRAF-activated noncoding RNA (BANCR) is aberrantly expressed in various tumor tissues and has been confirmed to function as a tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of BANCR in various carcinomas. Methods A comprehensive literature search of PubMed, Web of Science, EMBASE, Cochrane Library and the China National Knowledge Infrastructure (CNKI) was conducted to collect relevant articles. Results The pooled results showed a strong relationship between high BANCR expression and poor overall survival (OS) (HR (hazard ratio) =1.60, 95% confidence interval (CI): 1.19–2.15, P = 0.002) and recurrence-free survival (RFS) (HR = 1.53, 95% CI: 1.27–1.85, P < 0.00001). In addition, high BANCR expression predicted advanced tumor stage (OR (odds ratio) =2.39, 95% CI: 1.26–4.53, P = 0.008), presence of lymph node metastasis (OR = 2.03, 95% CI: 1.08–3.83, P = 0.03), positive distant metastasis (OR = 3.08, 95% CI: 1.92–4.96, P < 0.00001) and larger tumor sizes (OR = 1.63, 95% CI: 1.09–2.46, P = 0.02). However, no associations were found for smoking status (OR = 1.01, 95% CI: 0.65–1.56, P = 0.98), age (OR = 0.88, 95% CI: 0.71–1.09, P = 0.236) and sex (OR = 0.91, 95% CI: 0.72–1.16, P = 0.469). The sensitivity analysis of OS showed that the results of each publication were almost consistent with the combined results, and the merged results have high robustness and reliability. Conclusions The results showed that elevated BANCR expression was associated with unfavorable prognosis for most cancer patients, and BANCR could serve as a promising therapeutic target and independent prognostic predictor in most of cancer types.

scholarly journals High BANCR may manifest worse prognosis in human malignant carcinomas: An updated systematic review and meta-analysis

2020 ◽  
Author(s):  
Xu Gang ◽  
Shi xu Fang ◽  
Zhou Liu ◽  
Qiang Guo ◽  
Cheng Chen ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
China National Knowledge Infrastructure ◽  
Poor Overall Survival ◽  
Knowledge Infrastructure ◽  
Advanced Tumor ◽  
Non Coding Rna ◽  
Promising Therapeutic Target

Abstract BackgroundBRAF-activated non-coding RNA (BANCR) was reported to be aberrantly expressed in various tumor tissues and has been confirmed to function as tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of BANCR in various carcinomas.MethodsA comprehensive literature search of PubMed, Web of Science, EMBASE, Cochrane Library and the China National Knowledge Infrastructure (CNKI) was conducted to collected relevant articles.ResultsPooling results showed strong relevance of high BANCR expression and poor overall survival (OS) (HR=1.60, 95% confidence interval (CI): 1.19-2.15, P =0.002) and recurrence-free survival (RFS) (HR=1.53, 95%CI: 1.27-1.85, P <0.00001). In addition, high BANCR expression predicts advanced tumor stage (OR=2.39, 95%CI: 1.26-4.53, P =0.008), present lymph node metastasis (OR=2.03, 95%CI: 1.08-3.83, P =0.03), positive distant metastasis (OR=3.08, 95%CI: 1.92-4.96, P <0.00001) and bigger tumor size (OR: 1.63, 95%CI: 1.09-2.46, P =0.02).ConclusionsThe results showed that elevated BANCR expression was associated with unfavorable prognosis for most of cancer patients, and BANCR could be served as a promising therapeutic target and independent prognostic predictor for cancers.

scholarly journals The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Lele Cong ◽  
Hongyan Sun ◽  
Miao Hao ◽  
Qian Sun ◽  
Yang Zheng ◽  
...  
Keyword(s):  
Tumor Size ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Distant Metastases ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
Multiple Cancer ◽  
Advanced Tumor ◽  
Hazard Ratios

Objective. This meta-analysis was performed to identify the prognostic value of SLNCR1 in multiple cancer types. Methods. Electronic databases, including PubMed, EMBASE, and Web of Science, Cochrane Library, Medline, BioMed Central, Springer, Science Direct, and China National Knowledge Internet (CNKI), were searched for relevant studies up to August 2021, and the hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated to assess the relationship between SLNCR1 expression and overall survival (OS). Results. 12 studies with a total of 1155 patients with 9 different types of cancers were included in this meta-analysis. The pooled HR indicates that high SLNCR1 expression represented poorer prognosis of cancer (HR = 2.11, 95% CI: 1.59–2.80, I2 = 0%, P < 0.00001 ). Additionally, high SLNCR1 expression was correlated with TNM stage (odds ratio (OR): 1.72, 95% CI: 1.08–2.74, I2 = 62%, P = 0.02 ), lymph node metastasis (LNM) (OR:2.42, 95% CI: 1.61–3.64, I2 = 55%, P < 0.0001 ), and distant metastases (DM) (OR: 2.30, 95% CI: 1.50–3.55, I2 = 27%, P = 0.0002 ). However, no evidence was found for a relationship between SLNCR1 expression and clinical features such as tumor size (OR: 1.71, 95% CI: 0.93–3.14, I2 = 71%, P = 0.09 ), age (OR: 0.86, 95% CI: 0.68–1.08, I2 = 0%, P = 0.19 ), or gender (OR: 1.07, 95% CI: 0.64–1.81, I2 = 55%, P = 0.79 ). Conclusion. Our findings found that high SLNCR1 expression was associated with poor OS, advanced tumor stage, tumor size, LNM, and DM in multiple cancers, indicating that SLNCR1 may serve as a potential prognostic biomarker for cancer patients in China.

scholarly journals Prognostic value of hypoxia-inducible factor-1 alpha in nasopharyngeal carcinoma: a meta-analysis

2018 ◽  
Vol 33 (4) ◽  
pp. 447-454 ◽  
Author(s):  
Wenji Xie ◽  
Lihui Liu ◽  
Haixia He ◽  
Kaixuan Yang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Hypoxia Inducible Factor ◽  
Sensitivity Analyses ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
Poor Overall Survival ◽  
Hypoxia Inducible Factor 1 ◽  
Advanced Tumor

Background: Over the past 5 years, many studies have reported the prognostic value of hypoxia-inducible factor-1 alpha (HIF-1α) in nasopharyngeal carcinoma. However, the results have not reached a consensus until now. Therefore, we performed this meta-analysis to investigate the influence of HIF-1α expression on the prognosis and clinical characteristics in nasopharyngeal carcinoma. Methods: We searched PubMed, the Cochrane Library, Embase (via Ovid interface), Web of Science, and China National Knowledge Infrastructure electronic databases from their establishment to 6 December 2017. We calculated the hazard ratio (HR) and the odds ratio (OR) to assess the prognostic and clinicopathological values of HIF-1α, respectively. Q test and I2 statistic were applied to evaluate heterogeneity. We also conducted publication bias and sensitivity analyses. Results: A total of 18 studies with 1476 patients were included in our meta-analysis. We found HIF-1α expression was associated with poor overall survival (HR=1.77; 95% confidence interval (CI) 1.35, 2.32; P<0.001), poor progression-free survival (HR=1.72; 95% CI 1.22, 2.44; P=0.002), a higher rate of lymph node metastasis (OR=3.81; 95% CI 2.60, 5.58, P<0.001), and more advanced tumor stage (OR=2.98; 95% CI 1.79, 4.97; P<0.001). Conclusions: Our study demonstrated that HIF-1α could be an appropriate prognostic biomarker for nasopharyngeal carcinoma patients.

scholarly journals Prognostic and clinicopathological significance of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer: A meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250295
Author(s):  
Junhua Yu ◽  
Huiling Liu ◽  
Xueyun Zeng ◽  
Yujun Zhao ◽  
Dejun Jiang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Meta Analysis ◽  
Tumor Stage ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
C Reactive Protein ◽  
Cancer Specific Survival ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Advanced Tumor

Background In recent years, many studies have explored the potential prognostic utility of C-reactive protein/albumin ratio (CAR) in patients with gastric cancer (GC), however, the results remain conflicting. We thus performed a meta-analysis to determine the association of CAR and prognosis of GC. Methods This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. PubMed, Web of science, Embase, and Cochrane Library were searched. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and cancer-specific survival (CSS) of included studies were pooled to estimate the prognostic value of CAR. Results Eight studies with a total of 3,216 patients were included in this meta-analysis. High CAR was significantly associated with poor OS (HR = 1.59, 95%CI = 1.36–1.85, p<0.001) and worse CSS (HR = 1.65, 95%CI = 1.21–2.25, p = 0.002). In addition, high CAR was significantly associated with male sex (OR = 1.80, 95%CI = 1.31–2.47, p<0.001), advanced tumor stage (OR = 2.14, 95%CI = 1.48–3.09, p<0.001), and tumor size ≥3cm (OR = 2.69, 95%CI = 1.84–3.93, p<0.001). Conclusion Elevated pretreatment CAR is a prognostic marker of poor OS and CSS in patients with GC. Furthermore, high CAR levels are associated with clinicopathological features reflecting tumor progression.

scholarly journals Prognostic and clinicopathological significance of neutrophil-to-lymphocyte ratio in patients with oral cancer

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Yun Yang ◽  
Rongxun Liu ◽  
Feng Ren ◽  
Rui Guo ◽  
Pengfei Zhang
Keyword(s):  
Oral Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Tumor Stage ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Tumor Stage ◽  
Lymphocyte Ratio ◽  
Advanced Tumor ◽  
Oral Cancer Patients ◽  
Clinicopathological Significance

Objectives: Many studies have examined the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in oral cancer; however, the results are contradictory. We, therefore, conducted a meta-analysis aiming to clarify the prognostic value of the NLR in oral cancer patients. Methods: A literature search was conducted in the PubMed, Web of Science, and Embase databases. Stata version 12.0 was used for statistical analysis. Results: A total of 14 studies with 3216 patients were finally included. The results indicated that a high NLR was significantly associated with worse DFS (n=10, HR = 1.73, 95% confidence interval [CI] = 1.44–2.07, P<0.001). Similar results were observed for overall survival (OS) (n=9, HR = 1.61, 95% CI = 1.39–1.86, P<0.001). Moreover, a high NLR was also correlated with lymph node metastasis (n=7, odds ratio [OR] = 1.62, 95% CI = 1.32–1.98, P<0.001), advanced tumor stage (n=7, OR = 2.63, 95% CI = 2.12–3.25, P<0.001), T stage (n=6, OR = 3.22, 95% CI = 2.59–4.01, P<0.001), tumor differentiation (n=5, OR = 1.48, 95% CI = 1.03–2.11, P=0.033), and perineural invasion (n=4, OR = 1.83, 95% CI = 1.4–2.39, P<0.001). However, an elevated NLR was not correlated with gender. Conclusion: This meta-analysis showed that the NLR might be a potential independent prognostic factor in patients with oral cancer.

scholarly journals LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

2020 ◽  
Vol 40 (8) ◽  
Author(s):  
Shubo Tian ◽  
Jinglei Liu ◽  
Shuai Kong ◽  
Lipan Peng
Keyword(s):  
Survival Data ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Tumor Stage ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Features ◽  
High Expression ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
The Cochrane Library

Abstract Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 (DLX6-AS1) is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (hazard ratio (HR) = 2.30, confidence interval (95% CI): 1.70–3.09, P&lt;0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P&lt;0.01), tumor size (P&lt;0.01), lymph node metastasis (P&lt;0.01), and distant metastasis (P&lt;0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

scholarly journals Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1221
Author(s):  
Hyo Jung Cho ◽  
Geum Ok Baek ◽  
Moon Gyeong Yoon ◽  
Hye Ri Ahn ◽  
Ju A Son ◽  
...  
Keyword(s):  
Area Under The Curve ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Serum Markers ◽  
Advanced Tumor Stage ◽  
Protein Markers ◽  
Poor Overall Survival ◽  
Advanced Tumor ◽  
Normal Hepatocyte ◽  
Potential Biomarkers

Protein markers of hepatocellular carcinoma (HCC)-derived exosomes (HEX) have not yet been fully evaluated. Here, we identified novel protein contents of HEX and their clinical significance as biomarkers. Exosomes were isolated from human HCC cell lines and an immortalized normal hepatocyte cell line. Proteomic analyses revealed 15 markedly overexpressed proteins in HEX. The clinical relevance of the 15 proteins was analyzed in public RNA-sequencing datasets, and 6 proteins were selected as candidate of potential biomarkers. Serum CCT8 and CFL1 were markedly overexpressed in test cohort (n = 8). In the validation cohort (n = 224), the area under the curve (AUC) of serum CCT8 and CFL1 for HCC diagnosis was calculated as 0.698 and 0.677, respectively, whereas that of serum alpha-fetoprotein (AFP) was 0.628. The combination of three serum markers (CCT8, CFL1, and AFP) demonstrated the highest AUC for HCC diagnosis. (AUC = 0.838, 95% confidence interval = 0.773–0.876) Furthermore, higher serum CCT8 and CFL1 concentrations were significantly associated with the presence of vascular invasion, advanced tumor stage, poor disease-free survival, and poor overall survival. Cofilin-1 and CCT8, enriched proteins in HEX, were identified as potential diagnostic and prognostic serum biomarkers for HCC patients.

scholarly journals Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis

2021 ◽  
Vol 28 ◽  
pp. 107327482110505
Author(s):  
Zhenzhen Liang ◽  
Lianchang Liu ◽  
Chaowei Wen ◽  
Heya Jiang ◽  
Tianxia Ye ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Significance ◽  
Group Analysis ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Advanced Tumor Stage ◽  
Poor Overall Survival ◽  
Prognostic Features ◽  
Advanced Tumor ◽  
High Level

Purpose Since protein arginine methyltransferase 5 (PRMT5) is abnormally expressed in various tumors, in this study we aim to assess the association between PRMT5 and clinicopathological and prognostic features. Methods Electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, and the Cochrane Library were searched until July 25, 2021. The critical appraisal of the eligible studies was performed using the Newcastle–Ottawa Quality Assessment Scale. Pooled hazard ratios (HR) and pooled odds ratios (OR) were calculated to assess the effect. Engauge Digitizer version 12.1, STATA version 15.1, and R version 4.0.5 were used to obtain and analysis the data. Results A total of 32 original studies covering 15,583 patients were included. In our data, it indicated that high level of PRMT5 was significantly correlated with advanced tumor stage (OR = 2.12, 95% CI: 1.22-3.70, P =.008; I2 = 80.7%) and positively correlated with poor overall survival (HR = 1.59, 95% CI: 1.46-1.73, P < .001; I2 = 50%) and progression-free survival (HR = 1.53, 95% CI: 1.24-1.88, P < .001; I2 = 0%). In addition, sub-group analysis showed that high level of PRMT5 was associated with poor overall survival for such 5 kinds of cancers as hepatocellular carcinoma, pancreatic cancer, breast cancer, gastric cancer, and lung cancer. Conclusion For the first time we found PRMT5 was pan-cancerous as a prognostic biomarker and high level of PRMT5 was associated with poor prognosis for certain cancers.

Sign in / Sign up

Export Citation Format

Share Document